Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…
News
Globotriaosylsphingosine (LysoGb3) blood levels can be a useful and accurate biomarker to diagnose and monitor Fabry disease, rather than only using GLA mutational status, researchers suggest. The study, “Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?,” was published in the International Journal…
Fabry Stabilization index (FASTEX) is a valid, specific, and sensible instrument to accurately assess disease stability/progression in people with classic or non-classic Fabry disease, a large study showed. The results highlighted the value of using this tool in the clinical setting to monitor Fabry patients in a standardized way.
Use of Replagal — an enzyme replacement therapy (ERT) — during pregnancy and breastfeeding by women with Fabry disease appears to be safe for them and their children, according to a case series study. The study, “Enzyme Replacement Therapy in Pregnant Women with Fabry Disease: A Case…
To help reduce out-of-pocket medical expenses associated with managing and treating Fabry disease, an independent charitable patient assistance foundation has now added the disorder to its programs. Called The Assistance Fund (TAF), the organization assists eligible patients with insurance co-payments, coinsurance, deductibles, and other health-related expenses. Fabry disease…
Adjusting the dose of enzyme replacement therapy (ERT) for each patient may be essential to achieve complete neutralization of antibodies against the treatment, and reach better results to halt the progression of Fabry disease, according to a recent study. The study, “Dose-Dependent Effect of Enzyme Replacement…
Fabry disease patients who share the same genetic mutation in the GLA gene may experience different symptoms, a case report study has found. The study, “Clinical Diversity in Patients with Anderson-Fabry Disease with the R301Q Mutation,” was published in Internal Medicine. Fabry disease is a rare…
#NORDSummit – Major Issues on Table for Rare Disease Patients in US as Midterm Elections Approach
With the U.S. midterm elections now less than two weeks away, patient advocacy groups are solidly focused on a range of hot-button issues, from the Orphan Drug Tax Creditand affordable health insurance to future funding for rare disease research. Yet “whether Democrats take over the House or Senate, or…
The absence of white matter lesions (WMLs) in two specific regions of the brain may help physicians distinguish Fabry disease from multiple sclerosis and make an accurate diagnosis, a study has found. The study, “Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with…
Children and adolescents with Fabry disease who have no clinical history of stroke, show asymptomatic brain lesions, according to a follow-up neuroimaging study. Early detection of these lesions could make it easier for clinicians to begin treatment. The study, “Brain MRI findings in children and adolescents with Fabry disease” was published in the …
Recent Posts
- Idorsia outlines new Phase 3 program for lucerastat in Fabry disease
- Jeff’s Journey With Fabry Disease
- Eye vessel abnormalities may signal heart disease in Fabry patients
- We need more oral Fabry disease treatment options that reduce pain
- AMT-191 shows promise, but safety concerns prompt dosing pause
- Guest Voice: Believe us when we say we’re having a bad day
- Sangamo starts FDA submission seeking approval of Fabry gene therapy
- Managing my hypertension has required some trial and error
- Long-term use of lucerastat may protect kidneys in Fabry: Trial data
- Seeking good news as symptom relief eludes my children